

Year	Sales	Net Income	
2006	\$2,025,739,000	\$406,144,000	
2005	\$1,879,950,000	\$351,616,000	
2004	\$1,615,253,000	\$325,627,000	
Curr. Assets:	\$1,315,428,000	Curr. Liab.: \$520,432,000	P/E Ratio: 24.73
Plant, Equip.:	\$357,632,000	Total Liab.: \$547,423,000	Indic. Yr. Divd.: NA
Total Assets:	\$2,263,922,000	Net Worth: \$1,716,499,000	Debt/Equity: NA

Biomira Inc

70 South Main Street, Suite B and C, Cranbury, NJ, 08512; **PH:** 1-780-450-3761;
Fax: 1-780-450-4772; **http://**www.biomira.com; **Email:** ir@biomira.com

Year	Sales	Net Income
2006	\$1,189,000	\$1,189,000
2005	NA	NDQ
2004	Deloitte & Touche LLP	BIOM
2003	Computershare Investor Services Inc	89,390,000
2002	Pepper Hamilton LLP	-\$0.169
2001	24-582-7571	NA

Business: The company's principal activity is to develop cancer therapeutics by applying technology in immunotherapy and organic chemistry. The company is focused on synthetic therapeutic vaccines and innovative strategies for immunotherapy of cancer. The products of the company include therapeutic vaccine for breast cancer, b1p25 vaccine for lung cancer, autologous vaccine for lymphoma and liposomal interleukin-2, designed to boost the general immune system. The company has its operations in Canada, the United States, Barbados and Europe. Contract research and development accounted for 85% of 2001 revenues; licensing revenue from collaborative agreement, 12% and licensing and royalties, 3%.

Primary SIC and add'l.: 8731 2834 2836

CIK No.: 0000877984

Subsidiaries: Biomira, Biomira B.V., Biomira International Inc., Biomira USA Inc.

Officers: Marilyn Olson/VP - Clinical, Regulatory Affairs/\$183,000.00, Robert D. Aubrey/VP - Business Development/\$188,400.00, Edward A. Taylor/VP - Finance, Administration, CFO/\$217,400.00, Robert L. Kirkman/CEO, Dir., Pres., Peter Emtage/VP - Research, Development, Technical Operations

Directors: Michael C. Welsh/Corporate Governance, Nominating Committee, Chairperson - Audit Committee, Dir., Robert S. Blair/Dir., Rao R. Kogarty/VP, GM - Synthetic Biologies, Richard L. Jackson/Corporate Governance, Nominating Committee, Dir. - Executive Compensation Committee, Robert L. Kirkman/CEO, Dir., Pres., Vickery W. Stoughton/Audit Committee, Member, Chairperson - Financial Expert, Corporate Dir., Eric E. Baker/Executive Compensation Committee Member, Dir., Christopher S. Henney/Audit Committee, Corporate Governance, Nominating Committee, Dir.

Owners: Eric E. Baker, Vickery W. Stoughton, Alexander T. McPherson, Michael C. Welsh

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2005

Year	Sales	Net Income	
2005	\$3,755,000	-\$15,264,000	
2004	\$7,424,000	-\$9,669,000	
2003	\$2,640,000	-\$14,857,000	
Curr. Assets:	\$19,715,000	Curr. Liab.: \$2,619,000	
Plant, Equip.:	\$554,000	Total Liab.: \$3,604,000	Indic. Yr. Divd.: NA
Total Assets:	\$20,444,000	Net Worth: \$16,841,000	Debt/Equity: 0.1013

BioProgress Plc

15 -17 Cambridge Science Park, Milton Road, Cambridge, CB4 0FQ; **PH:** 44-1223394250;
Fax: 44-1223394251; **http://**www.bioprogress.com; **Email:** reception@bioprogress.com

Year	Sales	Net Income
2006	\$13,350,000	\$13,350,000
2005	63	NDQ
2004	Grant Thornton UK LLP	BPRG
2003	Fidelity Transfer Co	14,090,000
2002	NA	-\$2.7
2001	NA	NA

Business: The group's principal activity is the manufacture and distribution of products that use water soluble and biodegradable films. The products are applied in the dietary supplement, pharmaceutical, recreational and cosmetic industries and in other applications. The group also distributes flushable and biodegradable products for the medical and hygiene industries. The group is developing the XGEL(TM) Film System, for producing soft capsules that contain non-aqueous fillings in a variety of shapes and sizes. The non-aqueous filling is in either ingestible form in products such as vitamin, herbal and mineral supplements and in non-ingestible form in products such as painbalm and toiletries. Flushable and biodegradable products include osotony products for female personal hygiene. The group's manufacturing facilities are located at Cambridgeshire, England. Osotony products are sourced from Dambi in Wales, the United Kingdom and in the United States.

CIK No.: 0001210959

Subsidiaries: BioCustom Limited, BioProgress Technology Inc., BioProgress Technology International, Inc., BioProgress Technology Limited, BioTec Films LLC, D.H.A Nutrition Limited, Dexo BioGenerics Limited, Dexo BioPharm France SAS, Dexo LLC, Laboratoires Pharmaceutiques Dexo SA

Officers: Ian Thompson/Operations Dir., Georgina Godby/Sec., Richard Trevillion/Dir., CEO, Steve Martin/Dir., Commercial Development Dir., Peter Keen/Finance Dir., Executive Dir.

Directors: Anthony Knight/55/Non - Executive Dir., Member - Audit Committee - Remuneration Committee, John Dowell/Member - Advisory Board, Jonathan Hadgraft/Member - Advisory Board, Giancarlo Mennella/Member - Advisory Board, Anthony Knight/Non - Executive Dir., Barry Muncester/Member - Advisory Board, James Murray/Member - Advisory Board, Peter Ibbotson/Non Exec. Chmn., Richard Trevillion/Dir., CEO, Alan Clarke/Non - Executive Dir., Steve Martin/Dir., Commercial Development Dir., Christopher Muggleston/Member - Advisory Board

Owners: Mellon Nominees (UK) Limited/6.80%, Credit Suisse Securities (Europe) Limited/6.40%, LR Nominees Limited/5.20%, TD Waterhouse Nominees (Europe) Limited/9.20%, Barclayshare Nominees Limited/6.50%

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2005

Year	Sales	Net Income	
2005	\$8,005,000	-\$22,752,000	
2004	\$4,619,000	-\$13,419,000	
2003	\$1,684,911	-\$4,576,512	
Curr. Assets:	\$14,226,000	Curr. Liab.: \$3,446,000	
Plant, Equip.:	\$3,226,000	Total Liab.: \$6,771,000	Indic. Yr. Divd.: NA
Total Assets:	\$24,987,000	Net Worth: \$18,216,000	Debt/Equity: NA

Biopure Corp

11 Hurley St, Cambridge, MA, 02141; **PH:** 1-617-234-6500; **Fax:** 1-617-234-6505;
http://www.biopure.com; **Email:** pr@biopure.com

Year	Sales	Net Income
2006	\$0.535	\$0.535
2005	67	NDQ
2004	Ernst & Young LLP	BPUR
2003	American Stock Transfer & Trust Co	49,370,000
2002	Hogan & Hartson LLP	-\$0.671
2001	NA	868

Business: The group's principal activity is to develop, manufacture and market oxygen therapeutics. The products include hemopure and oxyglobin. Hemopure is an alternative to red blood cell transfusions as well as for use in the treatment of other critical care conditions. Oxyglobin is similar to hemopure except for its molecular distribution and has the same advantage over red blood cells. Oxyglobin is used in the treatment of canine anemia, mainly for veterinary purposes. Biopure (R), hemopure(R) and oxyglobin(R) are the registered trademarks of the group. The group's products are marketed through advertising, direct mail, educational seminars, conference calls, lectures at congresses and attendance at trade shows. The group has 24 patents and 11 applications pending relating to our oxygen therapeutics.

Primary SIC and add'l.: 2836 2834

CIK No.: 0000815508

Subsidiaries: Biopure Netherlands, BV, Biopure South Africa, Pty, Ltd., DeNovo Technologies Corporation, Reperfusion Systems Incorporated

Officers: Zafiris G. Zafirelis/61/Chmn., Pres., CEO/\$250,016.00, Geoffrey J. Filbey/VP - Engineering/\$175,396.00, Gerson A. Greenburg/VP - Medical Affairs, Francis H.

Murphy/CFO/\$170,832.00, W. Richard Light/VP - Technology Development, Jane Kober/Sr. VP, General Counsel, Sec./\$231,036.00, Virginia T. Rentko/VP - Preclinical Development, Barry L. Scott/VP - Business Development/\$185,215.00, Carl W. Rausch/CTO/\$353,842.00

Directors: Zafiris G. Zafirelis/61/Chmn., Pres., CEO, Martin B. Leon/Member - Scientific Advisory Board Chairperson, Howard A. Cohen/Member - Scientific Advisory Board, Daniel P. Harrington/48/Dir., David R. Holmes/Member - Scientific Advisory Board, Jay B. Pieper/62/Dir., David N. Judelson/75/Vice Chmn., Guido J. Neels/Dir., William W. O'neill/Member - Scientific Advisory Board, Spencer B. King/Member - Scientific Advisory Board, Charles A. Sanders/72/Lead Independent Dir., Kenneth Ouriel/Member - Scientific Advisory Board, Everett C. Koop/87/Dir.

Owners: Aktiengesellschaft/7.70%, Charles A. Sanders, Jane Kober, Guido Neels, Daniel P. Harrington, Geoffrey J. Filbey, Barry L. Scott, Francis H. Murphy

Financial Data: Fiscal Year End: 10/31 Latest Annual Data: 10/31/2005

Year	Sales	Net Income	
2005	\$2,110,000	-\$28,671,000	
2004	\$3,750,000	-\$41,665,000	
2003	\$4,019,000	-\$47,042,000	
Curr. Assets:	\$15,575,000	Curr. Liab.: \$4,052,000	
Plant, Equip.:	\$26,000,000	Total Liab.: \$5,301,000	Indic. Yr. Divd.: NA
Total Assets:	\$42,435,000	Net Worth: \$37,134,000	Debt/Equity: NA

Biosante Pharmaceuticals Inc

111 Barclay Blvd, Lincolnshire, IL, 60069; **PH:** 1-847-478-0500; **Fax:** 1-847-478-9152;
http://www.biosantepharm.com

Year	Sales	Net Income
2006	\$2.66	\$2.66
2005	14	AMEX
2004	Deloitte & Touche LLP	BPA
2003	NA	23,370,000
2002	Oppenheimer Wolff & Donnelly LLP	-\$0.43
2001	NA	605

Business: The group's principal activity is to develop prescription pharmaceutical products, vaccines and vaccine adjuvants using nanoparticle technology. In addition, it is also developing a pipeline of hormone replacement products to treat hormone deficiencies in men and women. Since its inception, it has been in the development stage.

Primary SIC and add'l.: 2834 8731

CIK No.: 0001023024

Subsidiaries: Structured Biologicals Inc., Teva Pharmaceuticals USA, Inc., Unimed Pharmaceuticals, Inc.

Officers: Phillip B. Donenberg/CFO, Treasurer, Sec. - Investor Relations/\$198,640.00, Steven J. Bell/VP - Research, Pre, Clinical Development/\$166,400.00, Stephen M. Simes/Vice Chmn., Pres., CEO/\$374,400.00

Directors: Stephen M. Simes/Vice Chmn., Pres., CEO, Fred Holubow/Dir., Member - Audit - Finance Committee, Nominating, Corporate Governance Committee, Ross J. Mangano/Dir., Member - Nominating - Corporate Governance Committee, Compensation Committee, Louis W. Sullivan/Chmn., Member - Audit - Finance Committee, Nominating, Corporate Governance Committee, Member Compensation Committee, Victor A. Morgenstern/Dir., Member - Nominating - Corporate Governance Committee, Compensation Committee, Peter Kjaer/Dir., Member - Audit - Finance Committee, Member Nominating - Corporate Governance Committee, Edward C. Rosenow/Dir., Member - Nominating - Corporate Governance Committee

Owners: Victor Morgenstern/5.20%, Louis W. Sullivan M.D., Angela Ho, Hans Michael Jebens/25.60%, Peter Kjaer/1.00%, Steven J. Bell Ph.D., Louis W. Sullivan/25.60%, JO & Co/8.50%, Fred Holubow, William Harris Investors, Inc./9.00%, Marcus Jebens/12.80%, Edward C. Rosenow III, M.D., Phillip B. Donenberg/1.00%, Ross Mangano/10.20%, Leah M. Lehman Ph.D., Marcus Jebens, Angela Ho/25.60%, Hans Michael Jebens/2.20%, Stephen M. Simes/2.50%, Avi Ben-Abraham M.D./5.40%

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2005

Year	Sales	Net Income	
2005	\$258,000	-\$9,651,000	
2004	\$78,000	-\$12,016,000	
2003	\$65,000	-\$5,959,000	
Curr. Assets:	\$9,347,000	Curr. Liab.: \$2,666,000	
Plant, Equip.:	\$216,000	Total Liab.: \$2,756,000	Indic. Yr. Divd.: NA
Total Assets:	\$9,575,000	Net Worth: \$6,819,000	Debt/Equity: NA